Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients

Transplantation

Volumn 90, Issue 2, 2010, Pages 221-222

  Trivedi, Hargovind L ^a   Terasaki, Paul I ^b   Feroz, Aziz ^a   Vanikar, Aruna V ^a   Trivedi, Varsha B ^a   Khemchandani, Sajni I ^a   Dave, Shruti D ^a   Shankar, Vangipuram ^c   Modi, Pranjal R ^a   Kaneku, Hugo ^b   Idica, Adam ^d   Everly, Matthew J ^d  

^a Institute of Transplantation Sciences   (India)

^b TERASAKI FOUNDATION LABORATORY   (United States)

^c MS Patel Cancer Centre   (India)

^d One Lambda Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADIPOSE TISSUE; ANTIBODY DETECTION; BLOOD GROUP TYPING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DONOR SPECIFIC TRANSFUSION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; LETTER; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MESENCHYMAL STEM CELL; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PLASMA CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSFUSION;

ADOLESCENT; ADULT; AGED; BORONIC ACIDS; CHILD; CLONAL DELETION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE; INFORMED CONSENT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROTEASE INHIBITORS; PYRAZINES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954904503     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181dde912     Document Type: Letter

References (7)

1. Flye MW, Burton K, Mohanakumar T, et al. Donor-specific transfusions have long-term beneficial effects for human renal allografts. Transplantation 1995; 60: 1395.
2. Marti HP, Henschkowski J, Laux G, et al. Effect of donor-specific transfusions on the outcome of renal allografts in the cyclospor-ine era. Transpl Int 2006; 19: 19.
3. Terasaki PI. The beneficial transfusion effect on kidney graft survival attributed to clonal deletion. Transplantation 1984; 37: 119.
4. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupuslike disease from nephritis. Nat Med 2008; 14: 748.
5. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
6. Everly MJ, Everly JJ, Susskind B, et al. Bort-ezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
7. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.